Tesamorelin is an approved drug, and the label rules out the reason it is sold
Tesamorelin is the peptide on a telehealth menu with a real, current FDA approval, which is why it gets sold hard. The approval is for one thing: reducing excess abdominal fat in adults who have HIV-associated lipodystrophy. The same prescribing information, in its limitations of use, says the drug is not indicated for weight loss management because it has a weight neutral effect. Both sentences are on the same page of the same document.
What this comes down to
- Approved under BLA 022505 to Theratechnologies, original approval November 10, 2010, and marketed as EGRIFTA, EGRIFTA SV and EGRIFTA WR.
- The indication is the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Nothing else.
- The label's limitations of use state that it is not indicated for weight loss management as it has a weight neutral effect, and that long-term cardiovascular safety has not been established.
- It is contraindicated in active malignancy and in pregnancy, and the label carries warnings on neoplasms, elevated IGF-1, fluid retention and glucose intolerance.
The approval, stated exactly
Drugs@FDA holds one application for tesamorelin: BLA 022505, sponsored by Theratechnologies, with the original approval recorded on November 10, 2010, and products listed as EGRIFTA powder at 1 mg and 2 mg per vial[2]. The current prescribing information, whose own effective date reads July 29, 2026, covers EGRIFTA SV and EGRIFTA WR[1]. The indication is one sentence long.
“EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.”
[1]
Directly beneath it, under Limitations of Use, the label rules out the thing most people are being offered tesamorelin for.
“EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect.”
[1]
A peptide marketed for fat loss carries an approved label saying, in the manufacturer's own words filed with the FDA, that it is weight neutral and not indicated for weight loss management. The approved use is redistribution of visceral fat in a specific disease, measured on a CT scan — not a number on a scale. If a seller's page implies otherwise, the label is the document that settles it.
What the trials measured
Two multicenter, randomized, double-blind, placebo-controlled studies supported the approval, each with a 26-week main phase and a 26-week extension. Seven hundred and forty patients with HIV-associated lipodystrophy and excess abdominal fat received the drug across the program, 543 of them during the initial 26-week placebo-controlled phase, randomized 2:1 against placebo. The primary endpoint in both was the percent change from baseline at week 26 in visceral adipose tissue, assessed by CT scan at the L4-L5 vertebral level[1].
PubMed, via the E-utilities API
tesamorelin AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 26. Positive control — semaglutide, identical filter — returned 316 through the identical filter in the same session.
Unfiltered, tesamorelin returns 121 records. Twenty-six randomized trials is what a completed development program looks like on this scale, and it is the number to hold the rest of the menu against: CJC-1295 returned 1 and TB-500 returned 0 through the identical filter the same day.
The trials outside the approval program are mostly about the same population — HIV-associated fatty liver disease, immune activation, neurocognitive outcomes[3]. That is a coherent research program aimed at one disease, not a general-purpose body-composition drug. Set it against the rest of the peptide table and it is the outlier in the good direction.
The safety information that comes with an approval
This is the underrated part. An approved drug arrives with a contraindication list somebody had to justify, and tesamorelin's is not short. The label contraindicates it in patients with disruption of the hypothalamic-pituitary axis, in patients with active malignancy, in known hypersensitivity to tesamorelin or the excipients, and in pregnancy[1].
- Increased risk of neoplasms. The drug releases endogenous growth hormone, a known growth factor; the label says to discontinue if there is any evidence of recurrent malignancy.
- Elevated IGF-1. The label says the effects of prolonged elevation are unknown and directs monitoring of IGF-1 levels during therapy.
- Fluid retention, which may include edema, arthralgia and carpal tunnel syndrome.
- Glucose intolerance or diabetes mellitus, with glucose evaluated before and during therapy.
- Most common adverse reactions above 5%: arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema and myalgia.
There is no contraindication list for BPC-157 or TB-500, because nobody ran the studies that would produce one. An approval is not only permission to sell — it is a file of things that went wrong, written down. The unapproved peptides look safer on paper for the worst possible reason.
What you are offered is usually not Egrifta
Five priced lines on our roster name tesamorelin, from five sellers — Live Vital, Transparent Meds, Pepti, Ryze Rx, and Trellis Vitality. The cheapest of them is $166 a month and the dearest $299, both read first-hand from the seller's own page. A compounded tesamorelin preparation is not EGRIFTA, is not reviewed by the FDA for safety, effectiveness or quality before it is sold, and does not arrive with the label above[5].
There is one genuine regulatory difference in tesamorelin's favor. A 503A compounder may use a bulk substance that is a component of an FDA-approved drug product, which tesamorelin is — that route is written into the statute[4]. For a peptide with no approval anywhere, that route does not exist. It still does not make the compounded vial the approved product, and what a certificate of analysis covers is a separate question again.
Questions people actually ask
What is tesamorelin approved for?
The reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. That is the entire indication on the approved prescribing information, which covers EGRIFTA SV and EGRIFTA WR under BLA 022505.
Is tesamorelin approved for weight loss?
No. The label's limitations of use state that it is not indicated for weight loss management as it has a weight neutral effect. The approved endpoint was percent change in visceral adipose tissue on a CT scan, not body weight.
Is compounded tesamorelin the same as Egrifta?
No. A compounded preparation is made outside the approval process and is not reviewed by the FDA for safety, effectiveness or quality before it is marketed. It also does not come with the approved label, its contraindications or its monitoring instructions.
What are the main safety warnings on the tesamorelin label?
It is contraindicated in active malignancy and in pregnancy, among others, and carries warnings for increased risk of neoplasms, elevated IGF-1 with monitoring required, fluid retention including carpal tunnel syndrome, and glucose intolerance or diabetes.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.EGRIFTA SV (tesamorelin) for injection — FDA prescribing information. U.S. Food and Drug Administration, Structured Product Labeling, 2026. Source · Document dated July 2026The prescribing information, with an SPL effective date of July 29, 2026, states the indication as the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy; states in Limitations of Use that the product is not indicated for weight loss management as it has a weight neutral effect and that long-term cardiovascular safety has not been established; lists contraindications including active malignancy and pregnancy; carries warnings for neoplasms, elevated IGF-1, fluid retention and glucose intolerance; names arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema and myalgia as the reactions above 5%; and describes two 26-week randomized double-blind placebo-controlled studies in which 740 patients received the drug, 543 during the initial placebo-controlled phase, with percent change in visceral adipose tissue by CT at L4-L5 as the primary endpoint.
- 2.Drugs@FDA: FDA-Approved Drugs, queried through the openFDA API. U.S. Food and Drug Administration, 2026. SourceOne application holds tesamorelin: BLA 022505, sponsor Theratechnologies, with the original submission approved November 10, 2010 and EGRIFTA listed as a powder at 1 mg and 2 mg per vial. A fabricated ingredient name returned no matches in the same run.
- 3.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-11, tesamorelin returned 121 records in total and 26 randomized controlled trials with the human indexing tag, against 316 for semaglutide, 1 for CJC-1295 and 0 for TB-500 through the identical filter in the same session.
- 4.21 U.S.C. 353a — Pharmacy compounding. Office of the Law Revision Counsel, United States Code, 2026. SourceA drug product may be compounded under section 503A using a bulk drug substance that, where no applicable monograph exists, is a component of a drug approved by the Secretary — the route tesamorelin qualifies for and an unapproved peptide does not.
- 5.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Compounded drugs are not FDA approved, are not reviewed for safety, effectiveness or quality before marketing, and a compounded drug is not a generic version of an approved product.
Key figures